The consultation services and assays offered by Dravya Discovery are derived from Dr Tripathi’s 15+ years’ experience in Ophthalmology, Neuroscience, and Immuno-oncology. This know-how from lab-based experience forms our recipe for success. Serving in Early Development Leadership Teams at big Pharma, Dr Tripathi has been responsible for maximising delivery of new clinical pipeline candidates. She successfully delivered stage-gate transition of several projects from Concept Assessment to Lead Identification-Lead Optimisation and preclinical development. Her scientific know-how has driven strategic directions of antibody therapeutics and botulinum neurotoxin (BoNT) therapeutics. She has coached project teams for target validation, antibody discovery, in vitro pharmacology, in vivo efficacy. Integrated data analytics expertise allows her to solve complex technical issues and develop fit-for-purpose screening assays (protein engineering, in vitro, ex vivo and in vivo). Having led various candidates to clinical development, Dr Tripathi’s previous work included developability to mitigate molecule structural liabilities of therapeutic biologics. Lastly, she has contributed to IND filings and is familiar with working in a GMP and GLP environment and required documentation needs. She has first author publications in several imminent journals such as Science and Nature, with a total citation record of >5000 citations. As evident, Dr Tripathi’s extensive project management experience from mid-sized and big Pharma would enable Dravya Discovery to achieve timely and successful completion of your projects within budget.

Ms. Vaishnav holds a Masters in Business Administration from University of Connecticut, MS in Cell Mol Biology from Illinois Institute of Technology and BS in Biotechnology, Biochemistry from St. Xaviers College. She has 10+ years in oncology research, project coordination and administration; she has worked in clinical/pre-clinical and therapeutic/chemopreventive research areas. Years working as lab researcher and transitioning to startup evaluation and market reserach has given her the spectrum of experience needed to better understand the business needs/pivots/agility required for a nimble and viable research organization.